Sign in
Taking peoplePhase 3

PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis

Key facts

Who runs it
University Hospital, Lille
Where
France22 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 3
People taking part
477 people, planned
Started
22 May 2026
Expected to end
May 2030
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • N-Acetylcysteine (NAC) Treatment
  • Prednisolone
  • Placebo of N-acetylcysteine
  • Placebo of Prednisolone 10mg
  • Prednisolone 10mg
Record updated
1 June 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Patients aged 18-75
  • Alcohol consumption of more than 40g/day (women) and 50g/day (men)
  • Recent onset of jaundice (<3 months)
  • Biopsy proven alcoholic hepatitis (transjugular liver biopsy)
  • Maddrey's discriminant function ≥ 32, defining severe alcoholic hepatitis
  • MELD score ≥ 17
  • Patients covered with social insurance
  • Patients having provided written informed consent to participate

Who cannot take part

  • Previous severe allergy or hypersensitivity to N-acetylcysteine (anaphylactic shock, Quincke edema, severe urticaria)
  • Treatment with corticosteroids, immunosuppression therapy or budesonide within 6 months before the study
  • Uncontrolled gastrointestinal bleeding
  • Hypersensitivity to any component of the medication
  • Type 1 hepatorenal syndrome before the initiation of treatment
  • Severe extrahepatic disease, with life expectancy < 6 months
  • Ongoing viral or parasitic infection
  • Untreated bacterial infection
  • Positive blood PCR in patients with positive antibodies against HCV
  • Patient carrying HBV or HIV
  • Any malignant tumor < 2 years (except skin carcinomas)
  • Tuberculosis < 5 years
  • Hepatocellular carcinoma
  • MELD score <17

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Only patients suffering from a severe form of alcoholic hepatitis (Maddrey's discriminant function greater than 32) require medical treatment. Oral prednisolone for 28 days is the only treatment which has been proven to improve short-term survival over placebo in patients with severe alcoholic hepatitis. However, prednisolone alone cannot be regarded as an ideal treatment because some patients still have a bad outcome despite being treated with corticosteroids. Response to treatment can be predicted by the Lille score, a simple tool that is calculated after 7 days of prednisolone course. The ideal binary cut-off of the Lille is 0.45, responders having a Lille score < 0.45 and non-responders having a Lille score ≥0.45. In terms of treatment management, approximately 30% of patients with severe alcoholic hepatitis do not take benefit from prednisolone and are classified as null responders by a Lille score greater than 0.56. In them, there is a consensus for stopping prednisolone after a 7-day course of treatment (Lille score is calculated after 7 days) while patients with a Lille score <0.56 continue treatment for a total of 30 days.

Read full original descriptionShow less

Numerous trials have attempted to test the impact of other strategies in association with prednisolone, but none of them has shown an improvement in survival (primary endpoint) as compared to prednisolone alone. These strategies include for instance pentoxifylline, amoxicillin-clavulanic acid and enteral nutrition.

Because oxidative stress is a major driver of liver injury during alcohol-related liver disease, antioxidants, especially N-acetylcysteine, have been tested for many years to treat alcoholic hepatitis. N-acetylcysteine alone does not seem to bring a survival benefit over placebo while it may improve outcome when combined to prednisolone.

Historically in severe alcoholic hepatitis, treatment is only given for one month. However, a significant proportion of patients still disclose impaired hepatic function after treatment has been stopped (e.g. 50% of patients still have a MELD score ≥17 after 60 days in). It is thus tempting to hypothesize that a proportion of patients will recover slowly and may take benefit from a prolonged treatment. Such strategy has been proposed in some old studies with relatively limited sample size but never tested with a rigorous approach.

In the present study, for the first time in alcoholic hepatitis, we will take into account the recent recommendations of international experts by choosing an innovative primary endpoint that does not only include mortality and evaluate this endpoint at the preferred timepoint of 90 days.

After more than 30 years of negative trials in severe alcoholic hepatitis, the present study is aimed to evaluate two important new strategies to decrease both mortality and liver impairment.

The 3 groups in the trial

  • NAC/Prednisolone/PlaceboTreatment being tested

    N-acetylcysteine for five days (day 1 to day 5) in combination with prednisolone 40 mg/day for a total of 30 days, followed by a placebo for 30 additional days

    Treatment: N-Acetylcysteine (NAC) Treatment, Prednisolone, and Placebo of Prednisolone 10mg

  • Placebo/Prednisolone/PlaceboExisting treatment, for comparison

    Placebo for five days (day 1 to day 5) in combination with prednisolone 40 mg/day for a total of 30 days, followed by a placebo for 30 additional days

    Treatment: Prednisolone, Placebo of N-acetylcysteine, and Placebo of Prednisolone 10mg

  • Placebo/Prednisolone/PrednisoloneTreatment being tested

    Placebo for five days (day 1 to day 5) in combination with prednisolone 40 mg/day for a total of 30 days, followed by prednisolone (tapering dose) for 30 additional days

    Treatment: Prednisolone, Placebo of N-acetylcysteine, and Prednisolone 10mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Criteria questions
Built from NCT06956482, who can take part
Record updated
1 June 2026